Bo’Ao Medical Tourism Pilot Zone fast-tracks 32 imported health products to market in H1’19



The Hainan Food and Drug Administration (HFDA) bureau revealed details of imported products granted special approval through the island’s Bo’Ao Medical Tourism Pilot Zone, which was given special permission to independently review and approve products urgently needed by patients in December 2018, as reported by GBI. According to the HFDA, a total of 32 foreign drugs and medical devices have been granted approval via the scheme during H1’19. These have been used to treat 61 patients, with no reports of adverse events.

Of the total, 11 import drugs were used to treat 23 patients, including 7 cancer therapies, 4 drugs for psoriasis and dermatitis. In addition, the HFDA has initiated a real world clinical data application pilot in the Bo’Ao Medical Tourism Pilot Zone earlier this year.


Reference:

Related news
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved local manufacturer Laboratorios Unidos’s Glucoglip (linagliptin), a first-mover generic version of Boehringer Ingelheim (BI)’s diabetes drug Trayenta.
According to GBI analysis, Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has granted marketing registration to Zavicefta (ceftazidime + avibactam), an antibacterial in-licensed by Pfizer from AstraZeneca.
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) issued market clearance to Abbott’s hormone replacement therapy Femoston (estradiol + dydrogesterone), according to GBI analysis.
Switzerland-based giant Novartis’s China unit announced market approval from the National Medical Products Administration (NMPA) for Gilenya (fingolimod), as a treatment for recurrent multiple sclerosis (MS) in patients aged 10 and over.
  • 1563520339966
  • China
  • Drug
Recent news
The Brazil-based Institute of Technology and Pharmaceuticals (Farmanguinhos), the drug making unit of the Oswaldo Cruz Foundation (Fiocruz), has delivered its pilot batches of hyperprolactinemia (HPRL) treatment cabergoline, the result of a Productive Development Partnership (PDP) with compatriot laboratory Cristália that concluded this year.
Brazil’s National Health Surveillance Agency (ANVISA) this week granted registration approval to Eli Lilly’s biologic drug Emgality (galcanezumab-gnlm), as revealed by GBI analysis.
The new Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE) opened for business on July 22.
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
The Shandong Centralized Drug Procurement platform released a notification in relation to public hospital drug and consumables procurement alliances.
The “4+7” volume-linked drug procurement pilot scheme introduced at the end of 2018 in 11 cities is set to be expanded to all regions of the country, following a meeting between the National Health Security Administration (NHSA) and industry stakeholders held last week.
  • 1563857070043
  • China
Analytics Snapshot


Analytics Snapshot